Vaccine Carriers

Novel adenovirus recombinant HIV-1 vaccine shows promise in murine study

Published in AIDS Weekly, May 26th, 2003

Wistar Institute scientists reported to the 10th conference on Retroviruses and Opportunistic Infections that they've developed a novel adenovirus recombinant HIV-1 vaccine.

Tests of the vaccine in mice revealed a transgene product specific CD8+ T-cell response with one dose.

A. R. Pinto and colleagues noted that "human recombinant adenovirus has been studied extensively as vaccine carrier for antigens from different pathogens including those from HIV-1. Although they can induce a very strong cellular and humoral immune response, giving promising results as vaccines, the pre-existing immunity of humans is expected to interfere with the efficacy of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-05-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry